Sung Ji Nam
Stock Analyst at Scotiabank
(2.15)
# 2,684
Out of 4,784 analysts
71
Total ratings
40.98%
Success rate
-4.44%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.14 | +75.44% | 5 | Mar 25, 2025 | |
| GH Guardant Health | Maintains: Sector Outperform | $47 → $52 | $43.14 | +20.54% | 4 | Feb 24, 2025 | |
| EXAS Exact Sciences | Maintains: Sector Outperform | $70 → $73 | $43.66 | +67.20% | 2 | Feb 24, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $7.67 | +56.45% | 2 | Feb 13, 2025 | |
| WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $362.16 | +24.25% | 2 | Feb 13, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $88 → $90 | $58.73 | +53.24% | 2 | Feb 6, 2025 | |
| TWST Twist Bioscience | Maintains: Sector Outperform | $54 → $62 | $40.36 | +53.62% | 5 | Feb 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Sector Perform | $605 → $650 | $500.16 | +29.96% | 13 | Feb 3, 2025 | |
| DHR Danaher | Initiates: Sector Perform | $265 | $205.85 | +28.73% | 1 | Dec 23, 2024 | |
| VCYT Veracyte | Maintains: Sector Outperform | $40 → $44 | $30.12 | +46.08% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $37 → $44 | $19.94 | +120.66% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.96 | +94.88% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $3 | $0.67 | +347.76% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $360 → $60 | $2.90 | +1,968.97% | 5 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $80.00 | +105.00% | 9 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $29 → $34 | $8.88 | +282.88% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.21 | +15.16% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.05 | - | 3 | Nov 24, 2020 |
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.14
Upside: +75.44%
Guardant Health
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $43.14
Upside: +20.54%
Exact Sciences
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $43.66
Upside: +67.20%
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $7.67
Upside: +56.45%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $362.16
Upside: +24.25%
Bio-Techne
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $58.73
Upside: +53.24%
Twist Bioscience
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $40.36
Upside: +53.62%
Thermo Fisher Scientific
Feb 3, 2025
Maintains: Sector Perform
Price Target: $605 → $650
Current: $500.16
Upside: +29.96%
Danaher
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $205.85
Upside: +28.73%
Veracyte
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $30.12
Upside: +46.08%
Nov 6, 2024
Maintains: Sector Outperform
Price Target: $37 → $44
Current: $19.94
Upside: +120.66%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.96
Upside: +94.88%
Sep 16, 2024
Initiates: Sector Outperform
Price Target: $3
Current: $0.67
Upside: +347.76%
Aug 28, 2024
Downgrades: Sector Perform
Price Target: $360 → $60
Current: $2.90
Upside: +1,968.97%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $80.00
Upside: +105.00%
Aug 13, 2024
Maintains: Sector Outperform
Price Target: $29 → $34
Current: $8.88
Upside: +282.88%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.21
Upside: +15.16%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.05
Upside: -